Comments
Suven Life Sciences in a notification to the stock exchanges on Thursday said it has initiated Phase 1 clinical trials and first dosing of a chemical entity intended for the treatment of major depressive disorder (MDD). The topline results from the study are expected during the January-March 2018 quarter, it further said. Suven Life Sciences, which had submitted the Investigational New Drug Application to conduct Phase 1 clinical trial for MDD under 505(1) of the Federal Food, Drug and Cosmetic Act (FDCA, USA), said the global anti-depressant market is valued at over $20 billion. The stock closed flat at ₹174.15 on the NSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.